Buy Diphenidine for sale online - USA vendor

Diphenidine: A Lesser-Known Dissociative Compound

Diphenidine, also known as DPD, DND, 1,2-DEP, and DPH, is a lesser-known novel dissociative substance of the diarylethylamine class. It is structurally similar to methoxphenidine (MXP) and ephenidine and is classified as an NMDA receptor antagonist.

Early Synthesis and Availability

The initial synthesis of diphenidine dates back to 1924. However, it wasn't pursued further. Following the 2013 UK arylcyclohexylamine ban, diphenidine, along with the related compound methoxphenidine, surfaced on the grey market. In 2014, there were instances of diphenidine being sold alongside synthetic cannabinoids in Japanese herbal incense blends, one of which was associated with a fatal overdose.

Subjective Effects

Diphenidine is reported to induce subjective effects that encompass stimulation, motor control impairment, pain relief, internal hallucinations, conceptual thinking, euphoria, and dissociation. Dissociation, a complex mental state characterized by perceptual distortions and a sense of detachment from both the environment and self, is a notable outcome. Anecdotal accounts have described high doses of diphenidine resulting in "bizarre somatosensory phenomena and transient anterograde amnesia. The effects of diarylethylamines bear similarities to arylcyclohexylamines such as ketamine and phencyclidine (PCP) as well as dextromethorphan (DXM).

Pharmacological Insights and Safety Concerns

There exists limited data regarding the pharmacological properties, metabolism, and toxicity of diphenidine in humans, and its history of human usage is exceedingly restricted. Some reports suggest that it may pose distinct toxicity risks compared to conventional dissociatives. Furthermore, it is believed to carry moderate to high abuse potential, making it crucial for individuals using this substance to adhere to harm reduction practices.

History and Culture

The synthesis of diphenidine was initially documented in 1924 and involved a nitrile displacement reaction similar to the one used later to discover phencyclidine in 1956. Following the 2013 UK ban on arylcyclohexylamines, diphenidine and methoxphenidine became accessible on the grey market.

In 2014, two instances emerged where diphenidine was combined with synthetic cannabinoids in Japanese herbal incense blends. One such blend contained diphenidine and 5-fluoro-AB-PINACA at concentrations of 289 mg/g and 55.5 mg/g, respectively. Another product that included AB-CHMINACA, 5F-AMB, and diphenidine was implicated in a fatal overdose.

Chemistry

Diphenidine falls within the diarylethylamine class, characterized by a phenethylamine framework with a substituted Rα in the phenyl ring. It possesses an amino group attached through the phenethylamine chain at the termini of the piperidine ring, categorizing it as a piperidine dissociative compound. Diphenidine structurally resembles MXP but lacks a 2-methoxy substitution on one of its phenyl rings.

Pharmacology

Diphenidine functions as an NMDA receptor antagonist. NMDA receptors are crucial for transmitting electrical signals between neurons in the brain and spinal column, and to allow signal transmission, these receptors must remain open. Dissociatives, like diphenidine, obstruct NMDA receptors, leading to diminished sensation, impaired movement, and the characteristic "hole" experience.

While some vendors have suggested that diphenidine acts as a dopamine reuptake inhibitor and a serotonin reuptake inhibitor with µ-opioid affinity, delivering typical dissociative effects, no comprehensive assessment of its affinity at the dopamine transporter has been conducted. If this hypothesis holds true, it offers an explanation for the substance's euphoric and often stimulating effects.

Furthermore, diphenidine and related diarylethylamines have been researched in vitro as potential treatments for neurotoxic injury. In this context, diphenidine may exhibit stronger NMDA receptor antagonist properties for neurogenesis, neurological repair, and neuroprotection compared to more commonly known NMDA receptor antagonistic dissociatives such as ketamine, dextromethorphan, PCP analogs, Iboga, and methoxetamine.

Subjective Effects

The general headspace of diphenidine is often described as euphoric and clear-headed in comparison to that of ketamine and reminiscent of ephenidine at lower dosages. Moderate or higher dosages can sometimes unwillingly turn very confusing and dysphoric without any apparent cause.

Physical Effects

• Stimulation
• Perception of bodily lightness - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate dosages by making the body feel light and effortless to move.
• Changes in felt bodily form
• Spatial disorientation
• Spontaneous bodily sensations - The diphenidine "body high" is a sharp, pleasurable tingling sensation which is location specific to the hands, feet and head.
• Tactile suppression - This partially to entirely suppresses one's own sense of touch, creating feelings of numbness within the extremities. It is responsible for the anaesthetic properties of this substance.
• Physical autonomy
• Increased salivation
• Increased heart rate
• Motor control loss - A loss of gross and fine motor control alongside of balance and coordination is prevalent within diphenidine and becomes especially strong at higher dosages. This means that one should be sitting down before the onset (unless one is experienced) in case of falling over and injuring oneself.
• Gait alteration
• Euphoria - This results in feelings of physical euphoria which range between mild pleasure to moderate all-encompassing bliss.
• Dizziness - Although uncommon, some people report dizziness under the influence of diphenidine.
• Nausea - It's worth noting that high dose diphenidine trips can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
• Orgasm suppression & Orgasm enhancement - Orgasm enhancement can sometimes also be present, even at higher doses, although this effect is not reliable.

Visual Effects

Suppression

• Visual acuity suppression
• Double vision - This component is prevalent at moderate to heavy dosages and makes reading impossible unless one closes an eye.
• Pattern recognition suppression - This effect generally occurs at higher dosages and makes one unable to recognize and interpret perceivable visual data.
• Frame rate suppression

Distortions

• Perspective distortions
• Environmental cubism
• Environmental orbism
• Scenery slicing

Geometry

The visual geometry produced by diphenidine can be described as very dark and bland when compared to that of ketamine or DXM and often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 and can be comprehensively described through its variations as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.

Hallucinatory states

At high dosages, diphenidine can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used psychedelics. These effects include internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - In comparison to other dissociatives, this effect can occur at heavy dosages, but is considerably less common than the same effect found within psychedelics and deliriants. It can be comprehensively described through its variations as delirious in believability, fixed in style, equal in new experiences and memory replays in content, autonomous in controllability and solid in style.

Cognitive Effects

The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:

• Anxiety suppression
• Disinhibition
• Depersonalization
• Derealization
• Creativity enhancement
• Dream potentiation
• Memory suppression
• Ego death
• Ego inflation
• Thought deceleration
• Increased music appreciation
• Analysis suppression
• Time distortion
• Cognitive euphoria
• Introspection
• Déjà vu
• Conceptual thinking
• Compulsive redosing
• Amnesia
• Increased libido - This is reported to be experienced at low to mid dosage ranges.

Disconnective Effects

• Tactile disconnection
• Consciousness disconnection
• Visual disconnection - This eventually results in the diphenidine's equivalent of the "K-hole" or more specifically, holes, spaces and voids alongside of structures.

Auditory Effects

• Auditory enhancement
• Auditory suppression
• Auditory distortion

Legal Status

Diphenidine is currently a legal grey area drug worldwide and is easily accessible through the use of online research chemical vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.

Canada: As of March 2016, MT-45 and its analogues, one of which being Diphenidine, are Schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.

Switzerland: Diphenidine is a controlled substance specifically named under Verzeichnis E.

Turkey: Diphenidine is a classed as drug and is illegal to possess, produce, supply, or import.